Value of FDG-PET in the management of non-small cell lung cancer

European Journal of Radiology

Volumn 45, Issue 1, 2003, Pages 49-59

  Stroobants, Sigrid ^a   Verschakelen, Johny ^a   Vansteenkiste, Johan ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Fluorodeoxyglucose; Lung cancer; Positron emission tomography; Review; Staging; Treatment response

Indexed keywords

CELLS; IMAGING TECHNIQUES; POSITRON EMISSION TOMOGRAPHY; PULMONARY DISEASES;

IMAGING MODALITY; POTENTIAL CLINICAL IMPLEMENTATION;

RADIOLOGY;

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; MEDRONATE TECHNETIUM TC 99M;

BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; CYTOTOXICITY; DIAGNOSTIC ACCURACY; DRUG UPTAKE; HUMAN; IMAGING SYSTEM; INTERMETHOD COMPARISON; LUNG NODULE; LUNG NON SMALL CELL CANCER; MEDIASTINUM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME; VALIDATION PROCESS;

CARCINOMA, NON-SMALL-CELL LUNG; COIN LESION, PULMONARY; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MEDIASTINUM; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0037214241     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0720-048X(02)00282-6     Document Type: Review

References (100)

1. Warburg O., Posener K., Negelein E. The metabolism of the carcinoma cell. Warburg O. The metabolism of tumors. 1931;29-169 Richard R. Smith, Inc, New York.
2. Pauwels E.K., McCready V.R., Stoot J.H., van Deurzen D.F. The mechanism of accumulation of tumour-localising radiopharmaceuticals. Eur. J. Nucl. Med. 25:1998;277-305.
3. Yamada S., Kubota K., Kubota R., Ido T., Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J. Nucl. Med. 36:1995;1301-1306.
4. Gurney J.W. Determining the likelihood of malignancy in solitary pulmonary nodules with Bayesian analysis. Part I. Theory. Radiology. 186:1993;405-413.
5. Yankelevitz D.F., Henschke C.I. Does 2-year stability imply that pulmonary nodules are benign? Am. J. Roentgenol. 168:1997;325-328.
6. Arroliga A.C., Matthay R.A. The role of bronchoscopy in lung cancer. Clin. Chest Med. 14:1993;87-98.
7. Geddes D.M., Elliott M. The solitary pulmonary nodule. Br. Med. J. 298:1989;67-68.
8. Santambrogio L., Nosotti M., Bellaviti N., Pavoni G., Radice F., Caputo V. CT-guided fine-needle aspiration cytology of solitary pulmonary nodules: a prospective, randomized study of immediate cytologic evaluation. Chest. 112:1997;423-425.
9. Larscheid R.C., Thorpe P.E., Scott W.J. Percutaneous transthoracic needle aspiration biopsy: a comprehensive review of its current role in the diagnosis and treatment of lung tumors. Chest. 114:1998;704-709.
10. Kubota K., Matsuzawa T., Fujiwara T., Ito M., Hatazawa J., Ishiwata K., Iwata R., Ido T. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J. Nucl. Med. 31:1990;1927-1932.
11. Gupta N.C., Frank A.R., Dewan N.A., Redepenning L.S., Rothberg M.L., Mailliard J.A., Phalen J.J., Sunderland J.J., Frick M.P. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 184:1992;441-444.
12. Dewan N.A., Gupta N.C., Redepenning L.S., Phalen J.J., Frick M.P. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. Chest. 104:1993;997-1002.
13. Slosman D.O., Spiliopoulos A., Couson F., Nicod L., Louis O., Lemoine R., Donath A., Junod A.F. Satellite PET and lung cancer: a prospective study in surgical patients. Nucl. Med. Commun. 14:1993;955-961.
14. Wahl R.L., Quint L.E., Greenough R.L., Meyer C.R., White R.I., Orringer M.B. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology. 191:1994;371-377.
15. Lowe V.J., Hoffman J.M., DeLong D.M., Patz E.F., Coleman R.E. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J. Nucl. Med. 35:1994;1771-1776.
16. Dewan N.A., Reeb S.D., Gupta N.C., Gobar L.S., Scott W.J. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis. Chest. 108:1995;441-446.
17. Duhaylongsod F.G., Lowe V.J., Patz E.F. Jr., Vaughn A.L., Coleman R.E., Wolfe W.G. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann. Thorac. Surg. 60:1995;1348-1352.
18. Bury T., Dowlati A., Paulus P., Corhay J.L., Benoit T., Kayembe J.M., Limet R., Rigo P., Radermecker M. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur. Respir. J. 9:1996;410-414.
19. Lowe V.J., Fletcher J.W., Gobar L., Lawson M., Kirchner P., Valk P., Karis J., Hubner K., Delbeke D., Heiberg E.V., Patz E.F., Coleman R.E. Prospective investigation of positron emission tomography in lung nodules. J. Clin. Oncol. 16:1998;1075-1084.
20. Prauer H.W., Weber W.A., Romer W., Treumann T., Ziegler S.I., Schwaiger M. Controlled prospective study of positron emission tomography using the glucose analogue [18f] fluorodeoxyglucose in the evaluation of pulmonary nodules. Br. J. Surg. 85:1998;1506-1511.
21. Halter G., Storck M., Guhlmann A., Frank J., Grosse S., Liewald F. FDG positron emission tomography in the diagnosis of peripheral pulmonary focal lesions. Thorac. Cardiovasc. Surg. 48:2000;97-101.
22. Imdahl A., Jenkner S., Brink I., Nitzsche E., Stoelben E., Moser E., Hasse J. Validation of FDG positron emission tomography for differentiation of unknown pulmonary lesions. Eur. J. Cardiothorac. Surg. 20:2001;324-329.
23. Croft D.R., Trapp J., Kernstine K., Kirchner P., Mullan B., Galvin J., Peterson M.W., Gross T., McLennan G., Kern J.A. FDG-PET imaging and the diagnosis of non-small cell lung cancer in a region of high histoplasmosis prevalence. Lung Cancer. 36:2002;297-301.
24. Gould M.K., Maclean C.C., Kuschner W.G., Rydzak C.E., Owens D.K. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. J. Am. Med. Assoc. 285:2001;914-924.
25. Erasmus J.J., McAdams H.P., Patz E.F. Jr., Coleman R.E., Ahuja V., Goodman P.C. Evaluation of primary pulmonary carcinoid tumors using FDG PET. Am. J. Roentgenol. 170:1998;1369-1373.
26. Higashi K., Ueda Y., Seki H., Yuasa K., Oguchi M., Noguchi T., Taniguchi M., Tonami H., Okimura T., Yamamoto I. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J. Nucl. Med. 39:1998;1016-1020.
27. Laitinen K.L., Soini Y., Mattila J., Paakko P. A typical bronchopulmonary carcinoids show a tendency toward increased apoptotic and proliferative activity. Cancer. 88:2000;1590-1598.
28. Kitamura H., Kameda Y., Nakamura N., Kanegae K., Zhao S., Hikosaka K., Hosokawa M., Kohanawa M., Tamaki N. Proliferative potential and p53 overexpression in precursor and early stage lesions of bronchioloalveolar lung carcinoma. Am. J. Pathol. 146:1995;876-887.
29. Higashi K., Ueda Y., Sakurai A., Wang X.M., Xu L., Murakami M., Seki H., Oguchi M., Taki S., Nambu Y., Tonami H., Katsuda S., Yamamoto I. Correlation of Glut-1 glucose transporter expression with FDG uptake in non-small cell lung cancer. Eur. J. Nucl. Med. 27:2000;1778-1785.
30. Bakheet S.M., Saleem M., Powe J., Al-Amro A., Larsson S.G., Mahassin Z. F-18 fluorodeoxyglucose chest uptake in lung inflammation and infection. Clin. Nucl. Med. 25:2000;273-278.
31. Kapucu L.O., Meltzer C.C., Townsend D.W., Keenan R.J., Luketich J.D. Fluorine-18-fluorodeoxyglucose uptake in pneumonia. J. Nucl. Med. 39:1998;1267-1269.
32. Franzius C., Biermann M., Hulskamp G., Frosch M., Roth J., Sciuk J., Schober O. Therapy monitoring in aspergillosis using F-18 FDG positron emission tomography. Clin. Nucl. Med. 26:2001;232-233.
33. Goo J.M., Im J.G., Do K.H., Yeo J.S., Seo J.B., Kim H.Y., Chung J.K. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology. 216:2000;117-121.
34. Brudin L.H., Valind S.O., Rhodes C.G., Pantin C.F., Sweatman M., Jones T., Hughes J.M. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur. J. Nucl. Med. 21:1994;297-305.
35. Mochizuki T., Tsukamoto E., Kuge Y., Kanegae K., Zhao S., Hikosaka K., Hosokawa M., Kohanawa M., Tamaki N. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J. Nucl. Med. 42:2001;1551-1555.
36. Vansteenkiste J., De Leyn P., Deneffe G., Menten J., Lerut T., Demedts M. Present status of induction treatment for N2 non-small cell lung cancer: a review. Eur. J. Cardiothorac. Surg. 13:1998;1-12.
37. Martini N., Kris M.G., Ginsberg R.J. The role of multimodality therapy in locoregional non-small cell lung cancer. Surg. Oncol. Clin. N. Am. 6:1997;769-791.
38. Webb W.R., Gatsouris S., Zerhouni E.A., Heelan R.T., Glazer G.M., Francis I.R., McNeil B.J. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiology Diagnostic Oncology Group. Radiology. 178:1991;705-713.
39. Dillemans B., Deneffe G., Verschakelen J., Decramer M. Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer. Eur. J. Cardiothorac. Surg. 8:1994;37-42.
40. Saunders C.A., Dussek J.E., O'Doherty M.J., Maisey M.N. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann. Thorac. Surg. 67:1999;790-797.
41. Valk P.E., Pounds T.R., Hopkins D.M., Haseman M.K., Hofer G.A., Greiss H.B., Myers R.W., Lutrin C.L. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann. Thorac. Surg. 60:1995;1573-1581.
42. Vansteenkiste J.F., Stroobants S.G., De Leyn P.R., Dupont P.J., Bogaert J., Maes A., Deneffe G.J., Nackaerts K.L., Verschakelen J.A., Lerut T.E., Mortelmans L.A., Demedts M.G. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J. Clin. Oncol. 16:1998;2142-2149.
43. Kernstine K.H., Mclaughlin K.A., Menda Y., Rossi N.P., Kahn D.J., Bushnell D.L., Graham M.M., Brown C.K., Madsen M.T. Can FDG-PET reduce the need for mediastinoscopy in potentially respectable non-small cell lung cancer? Ann. Thorac. Surg. 73:2002;394-401.
44. Vansteenkiste J.F., Stroobants S.G., Dupont P.J., De Leyn P.R., De Wever W.F., Verbeken E.K., Nuyts J.L., Maes F.P., Bogaert J.G. FDG-PET scan in potentially operable non-small cell lung cancer: do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases? The Leuven Lung Cancer Group. Eur. J. Nucl. Med. 25:1998;1495-1501.
45. Vansteenkiste J.F., Stroobants S.G., De Leyn P.R., Dupont P.J., Verschakelen J.A., Nackaerts K.L., Mortelmans L.A. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases Leuven Lung Cancer Group. Chest. 112:1997;1480-1486.
46. Bury T., Paulus P., Dowlati A., Corhay J.L., Weber T., Ghaye B., Schoffers J., Limet R., Albert A., Rigo P., Radermecker M. Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancer. Eur. Respir. J. 9:1996;2560-2564.
47. Weng E., Tran L., Rege S., Safa A., Sadeghi A., Juillard G., Mark R., Santigo S., Brown C., Mandelkern M. Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially resectable lung cancer. Am. J. Clin. Oncol. 23:2000;47-52.
48. Berlangieri S.U., Scott A.M., Knight S.R., Fitt G.J., Hennessy O.F., Tochon-Danguy H.J., Clarke C.P., McKay W.J. F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer. Eur. J. Cardiothorac. Surg. 16:(Suppl 1):1999;S25-S30.
49. 18FDG in patients with bronchogenic carcinoma. Chest. 108:1995;1617-1621.
50. Chin R. Jr., Ward R., Keyes J.W., Choplin R.H., Reed J.C., Wallenhaupt S., Hudspeth A.S., Haponik E.F. Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am. J. Respir. Crit. Care Med. 152:1995;2090-2096.
51. Scott W.J., Gobar L.S., Hauser L.G., Sunderland J.J., Dewan N.A., Sugimoto J.T. Detection of scalene lymph node metastases from lung cancer. Positron emission tomography. Chest. 107:1995;1174-1176.
52. Sazon D.A., Santiago S.M., Soo Hoo G.W., Khonsary A., Brown C., Mandelkern M., Blahd W., Williams A.J. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am. J. Respir. Crit. Care Med. 153:1996;417-421.
53. Steinert H.C., Hauser M., Allemann F., Engel H., Berthold T., von Schulthess G.K., Weder W. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology. 202:1997;441-446.
54. Sasaki M., Ichiya Y., Kuwabara Y., Akashi Y., Yoshida T., Fukumura T., Murayama S., Ishida T., Sugio K., Masuda K. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography. Eur. J. Nucl. Med. 23:1996;741-747.
55. Dwamena B.A., Sonnad S.S., Angobaldo J.O., Wahl R.L. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s - meta-analytic comparison of PET and CT. Radiology. 213:1999;530-536.
56. Hellwig D., Ukena D., Paulsen F., Bamberg M., Kirsch C.M. Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000. Pneumologie. 55:2001;367-377.
57. Vansteenkiste J.F., Stroobants S.G. The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology. Eur. Respir. J. 17:2001;802-820.
58. Parker S.L., Tong T., Bolden S., Wingo P.A. Cancer statistics 1997. CA Cancer J. Clin. 47:1997;5-27.
59. Quint L.E., Tummala S., Brisson L.J., et al. Distribution of distant metastases from newly diagnosed non-small cell lung cancer. Ann. Thorac. Surg. 62:1996;246-250.
60. Pantel K., Izbicki J., Passlick B., Angstwurm M., Haussinger K., Thetter O., Riethmuller G. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet. 347:1996;649-653.
61. Bury T., Barreto A., Daenen F., et al. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur. J. Nucl. Med. 25:1998;1244-1247.
62. Marom E.M., McAdams H.P., Erasmus J.J., Goodman P.C., Culhane D.K., Coleman R.E., Herndon P.E., Patz E.F. Jr. Staging non-small cell lung cancer with whole-body PET. Radiology. 212:1999;803-809.
63. Oliver T.W. Jr, Bernardino M.E., Miller J.I., Mansour K., Greene D., Davis W.A. Radiology Isolated adrenal masses in nonsmall-cell bronchogenic carcinoma. Radiology. 153:1984;217-218.
64. Nielsen M.E. Jr., Heaston D.K., Dunnick N.R., Korobkin M. Preoperative CT evaluation of adrenal glands in non-small cell bronchogenic carcinoma. Am. J. Roentgenol. 139:1982;317-320.
65. Pagani J.J. Non-small cell lung carcinoma adrenal metastases. Computed tomography and percutaneous needle biopsy in their diagnosis. Cancer. 53:1984;1058-1060.
66. Ettinghausen S.E., Burt M.E. Prospective evaluation of unilateral adrenal masses in patients with operable non-small-cell lung cancer. J. Clin. Oncol. 9:1991;1462-1466.
67. Erasmus J.J., Patz E.F., McAdams H.P., Murray J.G., Herndon J., Coleman R.E., Goodman P.C. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. Am. J. Roentgenol. 168:1997;1357-1360.
68. Boland G.W., Goldberg M.A., Lee M.J., Mayo-Smith W.W., Dixon J., McNicholas M.M., Mueller P.R. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 194:1995;131-134.
69. Yun M., Kim W., Alnafisi N., Lacorte L., Jang S., Alavi A. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J. Nucl. Med. 42:2001;1795-1799.
70. Patz E.F. Jr., Erasmus J.J., McAdams H.P., Connolly J.E., Marom E.M., Goodman P.C., Leder R.A., Keogan M.T., Herndon J.E. Lung cancer staging and management: comparison of contrast-enhanced and nonenhanced helical CT of the thorax. Radiology. 212:1999;56-60.
71. Hustinx R., Paulus P., Jacquet N., Jerusalem G., Bury T., Rigo P. Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases. Ann. Oncol. 9:1998;397-401.
72. Griffeth L.K., Rich K.M., Dehdashti F., Simpson J.R., Fusselman M.J., McGuire A.H., Siegel B.A. Brain metastases from non-central nervous system tumors: evaluation with PET. Radiology. 186:1993;37-44.
73. Weder W., Schmid R.A., Bruchhaus H., Hillinger S., von Schulthess G.K., Steinert H.C. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann. Thorac. Surg. 66:1998;886-892.
74. Pieterman R.M., van Putten J.W., Meuzelaar J.J., Mooyaart E.L., Vaalburg W., Koeter G.H., Fidler V., Pruim J., Groen H.J. Preoperative staging of non-small-cell lung cancer with positron-emission topography. N. Engl. J. Med. 343:2000;254-261.
75. 18FDG positron emission tomography in the staging of non-small cell lung cancer. Eur. Respir. J. 10:1997;2529-2534.
76. van Tinteren H., Hoekstra O.S., Smit E.F., van den Bergh J.H., Schreurs A.J., Stallaert R.A., van Velthoven P.C., Comans E.F., Diepenhorst F.W., Verboom P., van Mourik J.C., Postmus P.E., Boers M., Teule G.J. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 359:2002;1388-1393.
77. MacManus M.P., Hicks R.J., Matthews J.P., Hogg A., McKenzie A.F., Wirth A., Ware R.E., Ball D.L. High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 50:2001;287-293.
78. Kalff V., Hicks R.J., MacManus M.P., Binns D.S., McKenzie A.F., Ware R.E., Hogg A., Ball D.L. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J. Clin. Oncol. 19:2001;111-118.
79. WHO handbook for reporting results of cancer treatment. Geneva (Switzerland): World Organisation of Health Offset Publication No 48, 1979.
80. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., Van Glabbeke M., van Oosterom A.T., Christian M.C., Gwyther S.G. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92:2000;205-216.
81. Minn H., Joensuu H., Ahonen A., Klemi P. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer. 61:1988;1776-1781.
82. Higashi K., Clavo A.L., Wahl R.L. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J. Nucl. Med. 34:1993;414-419.
83. Wahl R.L., Zasadny K., Helvie M., Hutchins G.D., Weber B., Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J. Clin. Oncol. 11:1993;2101-2111.
84. Schelling M., Avril N., Nahrig J., Kuhn W., Romer W., Sattler D., Werner M., Dose J., Janicke F., Graeff H., Schwaiger M. Positron emission tomography using Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J. Clin. Oncol. 18:2000;1689-1695.
85. Smith I.C., Welch A.E., Hutcheon A.W., Miller I.D., Payne S., Chilcott F., Waikar S., Whitaker T., Ah-See A.K., Eremin O., Heys S.D., Gilbert F.J., Sharp P.F. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J. Clin. Oncol. 18:2000;1676-1688.
86. Romer W., Hanauske A.R., Ziegler S., Thodtmann R., Weber W., Fuchs C., Enne W., Herz M., Nerl C., Garbrecht M., Schwaiger M. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood. 91:1998;4464-4471.
87. Brucher B.L., Weber W., Bauer M., Fink U., Avril N., Stein H.J., Werner M., Zimmerman F., Siewert J.R., Schwaiger M. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann. Surg. 233:2001;300-309.
88. van Oosterom A.T., Judson I., Verweij J., Stroobants S., Donato di Paola E., Dimitrijevic S., Martens M., Webb A., Sciot R., Van Glabbeke M., Silberman S., Nielsen O.S. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 358:2001;1421-1423.
89. Vansteenkiste J.F., Stroobants S.G., De Leyn P.R., Dupont P.J., Verbeken E.K. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group. Ann. Oncol. 9:1998;1193-1198.
90. Akhurst T., Downey R.J., Ginsberg M.S., Gonen M., Bains M., Korst R., Ginsberg R.J., Rusch V.W., Larson S.M. An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann. Thorac. Surg. 73:2002;259-264.
91. Ryu J.S., Choi N.C., Fischman A.J., Lynch T.J., Mathisen D.J. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer. 35:2002;179-187.
92. Kumar P., Herndon J., Langer M., Kohman L.J., Elias A.D., Kass F.C., Eaton W.L., Seagren S.L., Green M.R., Sugarbaker D.J. Patterns of disease failure after trimodality treatment for non-small cell lung carcinoma pathologic stage IIIA(N2). Cancer. 77:1996;2393-2399.
93. Vansteenkiste J., De Leyn P., Deneffe G., Menten J., Lerut T., Demedts M. Present status of induction treatment for N2 non-small cell lung cancer: a review. Eur. J. Cardiothorac. Surg. 13:1998;1-12.
94. Martini N., Kris M.G., Ginsberg R.J. The role of multimodality therapy in locoregional non-small cell lung cancer. Surg. Oncol. Clin. N. Am. 6:1997;769-791.
95. Pisters K.M., Kris M.G., Gralla R.J., Zaman M.B., Heelan R.T., Martini N. Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials. J. Clin. Oncol. 11:1993;1757-1762.
96. Bueno R., Richards W.G., Swanson S.J., Jaklitsch M.T., Lukanich J.M., Mentzer S.J., Sugarbaker D.J. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann. Thorac. Surg. 70:2000;1826-1831.
97. Choi N.C., Carey R.W., Daly W., Mathisen D., Wain J., Wright C., Lynch T., Grossbard M., Grillo H. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J. Clin. Oncol. 15:1997;712-722.
98. Voltolini L., Luzzi L., Ghiribelli C., Paladini P., Di Bisceglie M., Gotti G. Results of induction chemotherapy followed by surgical resection in patients with stage IIIA (N2) non-small cell lung cancer: the importance of the nodal down-staging after chemotherapy. Eur. J. Cardiothorac. Surg. 20:2001;1106-1112.
99. Pauwels M., Van Schil P., De Backer W., Van den Brande F., Eyskens E. Repeat mediastinoscopy in the staging of lung cancer. Eur. J. Cardiothorac. Surg. 14:1998;271-273.
100. Van steenkiste J., Stroobants S., Hoekstra C., Smit E., van Zandwijk N., Schramel F., Biesma B., Nackaerts K., Van Raemdonck D., Lammertsma A., Mortelmans L. 18 fluorodeoxyglucose positron emission tomography (PET) in the assessment of induction chemotherapy in stage IIIA-N2 NSCLC: a multi-centre prospective study. Proc. Am. Soc. Clin. Oncol. 20:2001;313A. (abstract).